急诊科MRSA鼻拭子PCR用于抗生素降阶梯治疗
本研究为单中心观察性队列研究,纳入341例急诊入院的成人肺炎患者。结果显示,有MRSA PCR鼻拭子且阴性者中35.2%接受了>1剂MRSA活性药物,而无拭子者该比例为52%(p<0.01)。次要结局除30天再入院率外无显著差异:无拭子者再入院率1.6%,有拭子者6.6%。作者认为急诊MRSA PCR鼻拭子可能作为肺炎早期MRSA活性抗生素降阶梯的有用工具。
要点
- 急诊肺炎患者中,MRSA鼻拭子PCR阴性者35.2%接受>1剂MRSA活性药物,无拭子者52%(p<0.01)。
- MRSA鼻拭子PCR在肺炎中的阴性预测值为96.1-99.2%,可用于早期降阶梯MRSA活性药物。
- 次要结局(AKI、阳性MRSA培养、住院时长、院内死亡)无显著差异;再入院率无拭子者1.6% vs 有拭子者6.6%。
- 作者结论:急诊MRSA PCR鼻拭子可能作为肺炎早期MRSA活性抗生素降阶梯的有用工具。
适用人群与场景
- 急诊入院的成人肺炎患者(通过ICD-10编码识别,出院诊断肺炎)。
研究设计与关键结果
- 单中心观察性队列研究,纳入341例急诊入院的成人肺炎患者。
- 主要结局:有MRSA PCR鼻拭子且阴性者中35.2%接受>1剂MRSA活性药物,无拭子者52%(p<0.01)。
- 次要结局:除再入院率外无显著差异;无拭子者再入院率1.6%,有拭子者6.6%。
- 次要结局包括AKI、阳性MRSA培养(血、痰、气管吸出物)、住院时长、院内死亡、30天再入院率,均无显著差异(再入院率除外)。
证据类型、等级与局限
- 证据类型:单中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急诊MRSA PCR鼻拭子可能作为肺炎早期MRSA活性抗生素降阶梯的有用工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) nasal swab polymerase chain reaction (PCR) assay has a 96.1-99.2% negative predictive value (NPV) in pneumonia and may be used for early de-escalation of MRSA-active antibiotic agents. Xu (2018), File (2010) [1,2].
OBJECTIVE: The objective of our study was to determine if a negative MRSA PCR nasal swab collected in the emergency department (ED) improves early MRSA-active antibiotic de-escalation.
METHODS: A single center observational cohort study used ICD-10 codes to identify records for adults admitted to the ED with a hospital discharge diagnosis of pneumonia. The primary outcome was proportion of patients with early de-escalation on an MRSA-active agent (≤ 1 dose). Secondary outcomes included rate of acute kidney injury (AKI), positive MRSA cultures (blood culture, respiratory sputum, tracheal aspirate), hospital length of stay (LOS), in-hospital mortality, and 30-day readmission rates.
RESULTS: A total of 341 patients were included in the study. Of the patients with an MRSA PCR swab, 35.2% of patients with a negative swab received >1 dose of MRSA-active agent compared to 52% of patients without an MRSA nasal swab (p < 0.01). There were no significant differences in secondary outcomes except readmission rate of 1.6% of patients that did not have an MRSA swab in the ED vs 6.6% of patients that received an MRSA swab in the ED.
CONCLUSION AND RELEVANCE: MRSA PCR nasal swabs in the ED may serve as a useful tool for early MRSA-active antibiotic de-escalation when treating pneumonia.
参考来源
- Sindelar MA, Zepeski AE, Lawler BJ, et al. MRSA nasal swab PCR to de-escalate antibiotics in the emergency department. Am J Emerg Med. 2022. PMID: 35313228. doi:10.1016/j.ajem.2022.03.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。